{{expand|time=2018-02-14T13:32:29+00:00}}
{{Infobox medical condition
| Name = 进行性多灶性白质脑病
| Image = 
| Caption = 
| DiseasesDB = 10718
| ICD10 = {{ICD10|A|81|2|a|80}}
| ICD9 = {{ICD9|046.3}}
| ICDO = 
| OMIM = 
| MedlinePlus = 000674
| eMedicineSubj = radio
| eMedicineTopic = 573
| MeshID = D007968
}}
'''进行性多灶性白质脑病'''（{{lang-en|''Progressive multifocal leukoencephalopathy''}}，''PML''），或称进行性多灶性[[脑白质炎|脑白质炎]]，是一种以进行性脑损伤和多灶性[[脑白质|脑白质]][[炎症|炎症]]为特点的一种罕见并往往致命的[[病毒|病毒]]性疾病。本病几乎发生于严重的[[免疫缺陷|免疫缺陷]]患者，例如接受[[免疫抑制|免疫抑制]]药物的[[器官移植|器官移植]]患者<ref>{{Cite journal|last=Mateen|first=Farrah J.|last2=Muralidharan|first2=RajaNandini|last3=Carone|first3=Marco|last4=van de Beek|first4=Diederik|last5=Harrison|first5=Daniel M.|last6=Aksamit|first6=Allen J.|last7=Gould|first7=Mary S.|last8=Clifford|first8=David B.|last9=Nath|first9=Avindra|date=2011-08|title=Progressive multifocal leukoencephalopathy in transplant recipients|url=https://onlinelibrary.wiley.com/doi/10.1002/ana.22408|journal=Annals of Neurology|language=en|volume=70|issue=2|doi=10.1002/ana.22408|pmc=PMC4910883|pmid=21823157}}</ref>，接受特定[[化疗|化疗]]药物的患者，接受[[那他珠单抗|那他珠单抗]]（一种[[单克隆抗体|单克隆抗体]]，用于治疗[[多发性硬化|多发性硬化]]）的患者<ref>{{Cite web|title=SDEF: Third Psoriatic PML Case Raises More Concerns About Efalizumab|url=http://www.medpagetoday.com/MeetingCoverage/SDEF/12849|archive-url=https://web.archive.org/web/20140312212602/http://www.medpagetoday.com/MeetingCoverage/SDEF/12849|archive-date=2014-03-12|accessdate=2014-04-11|dead-url=yes}}</ref>，长期使用[[依法利珠单抗|依法利珠单抗]]治疗[[银屑病|银屑病]]的患者，使用[[brentuximab|brentuximab]]（[[Raptiva|Raptiva]]）治疗[[霍奇金淋巴瘤|霍奇金淋巴瘤]]的患者<ref>{{cite web|title=FDA Approval for Brentuximab Vedotin|url=http://www.cancer.gov/cancertopics/druginfo/fda-brentuximabvedotin|archive-url=https://web.archive.org/web/20140406215722/http://www.cancer.gov/cancertopics/druginfo/fda-brentuximabvedotin|archive-date=2014-04-06|accessdate=2014-04-11|dead-url=no}}</ref>，以及[[艾滋病|艾滋病]]患者。

进行性多灶性白质脑病是由[[JC病毒|JC病毒]]感染所导致。在免疫力正常的人群中[[JC病毒|JC病毒]]感染能够被[[免疫系统|免疫系统]]所控制，而免疫缺陷病人往往不能抵抗[[JC病毒|JC病毒]]的侵袭。

==病因==
===JC病毒感染===
进行性多灶性白质脑病的病因是一种称为JC病毒(JCV)的多瘤病毒。最近的出版物表明，39%<ref>{{Cite journal|last=Kean|first=Jaime M.|last2=Rao|first2=Suchitra|last3=Wang|first3=Michael|last4=Garcea|first4=Robert L.|date=2009-03-27|editor-last=Atwood|editor-first=Walter J.|title=Seroepidemiology of Human Polyomaviruses|url=https://dx.plos.org/10.1371/journal.ppat.1000363|journal=PLoS Pathogens|language=en|volume=5|issue=3|doi=10.1371/journal.ppat.1000363|issn=1553-7374|pmc=PMC2655709|pmid=19325891}}</ref>至58%<ref>{{Cite journal|last=Egli|first=Adrian|last2=Infanti|first2=Laura|last3=Dumoulin|first3=Alexis|last4=Buser|first4=Andreas|last5=Samaridis|first5=Jacqueline|last6=Stebler|first6=Christine|last7=Gosert|first7=Rainer|last8=Hirsch|first8=Hans H.|date=2009-03-15|title=Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors|url=https://academic.oup.com/jid/article-lookup/doi/10.1086/597126|journal=The Journal of Infectious Diseases|language=en|volume=199|issue=6|doi=10.1086/597126|issn=0022-1899|pmid=19434930}}</ref>的一般人群对JC病毒抗体呈血清阳性，表明当前或以前感染过该病毒。其他出版物将这一百分比定为总人口的70%至90%<ref name="shakel">{{Cite journal|last=Shackelton|first=Laura A.|last2=Rambaut|first2=Andrew|last3=Pybus|first3=Oliver G.|last4=Holmes|first4=Edward C.|date=2006-10-15|title=JC Virus Evolution and Its Association with Human Populations|url=https://journals.asm.org/doi/10.1128/JVI.00441-06|journal=Journal of Virology|language=en|volume=80|issue=20|doi=10.1128/JVI.00441-06|issn=0022-538X|pmc=PMC1617318|pmid=17005670}}</ref>。JC病毒在大约三分之一的成年人口中导致持续的无症状感染，只有当免疫系统被严重削弱时，病毒才会引起疾病。

===免疫抑制===
PML 最常见于 HIV-1 感染者；在有效的[[抗逆转录病毒疗法|抗逆转录病毒疗法]]出现之前，多达 5% 的[[艾滋病|艾滋病]]患者最终发展为进行性多灶性白质脑病。尚不清楚为什么艾滋病患者比其他免疫抑制疾病更频繁地发生进行性多灶性白质脑病；一些研究表明，HIV 对脑组织或JC病毒本身的影响使JC病毒更有可能在大脑中变得活跃并增加其破坏性的炎症作用<ref name="pmid12709870">{{Cite journal|last=Berger|first=Joseph R|date=2003-01|title=Progressive Multifocal Leukoencephalopathy in Acquired Immunodeficiency Syndrome: Explaining the High Incidence and Disproportionate Frequency of the Illness Relative to Other Immunosuppressive Conditions|url=http://link.springer.com/10.1080/13550280390195261|journal=Journal of Neurovirology|language=en|volume=9|issue=s1|doi=10.1080/13550280390195261|issn=1355-0284|pmid=12709870|s2cid=17171153}}</ref>。

===与多发性硬化治疗===
那他珠单抗（Natalizumab）于2004年被[[FDA|FDA]]批准用于治疗多发性硬化。在与三起进行性多灶性白质脑病案件有关后，其制造商随后将其撤出市场，这三个初始病例都服用那他珠单抗和[[干扰素β-1a|干扰素β-1a]]。经过安全审查，该药物于 2006 年作为多发性硬化单一疗法在特殊处方计划下重新上市，而截至2011年5月，已在多发性硬化患者中报告了130多例PML，所有患者均服用那他珠单抗超过一年。大约 20% 的患有PML的多发性硬化患者死亡，其余的大多数幸存者都留有残疾<ref name="pmid21777829">{{Cite journal|last=Kappos|first=Ludwig|last2=Bates|first2=David|last3=Edan|first3=Gilles|last4=Eraksoy|first4=Mefkûre|last5=Garcia-Merino|first5=Antonio|last6=Grigoriadis|first6=Nikolaos|last7=Hartung|first7=Hans-Peter|last8=Havrdová|first8=Eva|last9=Hillert|first9=Jan|last10=Hohlfeld|first10=Reinhard|last11=Kremenchutzky|first11=Marcelo|date=2011-08|title=Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring|url=https://pubmed.ncbi.nlm.nih.gov/21777829|journal=The Lancet. Neurology|volume=10|issue=8|doi=10.1016/S1474-4422(11)70149-1|issn=1474-4465|pmid=21777829|s2cid=15639613}}</ref>。FDA 没有将该药物从市场上撤出，因为收益大于风险<ref>{{cite web|last=Hitti|first=M|date=2008-08-01|title=MS Drug Tysabri Tied to Brain Infection|url=http://www.webmd.com/multiple-sclerosis/news/20080801/ms-drug-tysabri-tied-to-brain-infection|publisher=[[WebMD|WebMD]]|archive-url=https://web.archive.org/web/20181120221058/https://www.webmd.com/multiple-sclerosis/news/20080801/ms-drug-tysabri-tied-to-brain-infection|archive-date=2018-11-20|access-date=2010-08-31|dead-url=no}}</ref>。

==治疗==
没有任何药物能有效抑制或治愈病毒感染。因此，治疗旨在逆转免疫缺陷以减缓或阻止疾病进展。对于免疫抑制患者，这意味着停止药物或使用血浆置换来加速去除使患者处于进行性多灶性白质脑病风险中的生物制剂<ref name="NIH">{{cite web|date=2014-02-14|title=Progressive Multifocal Leukoencephalopathy Information Page|url=https://www.ninds.nih.gov/disorders/all-disorders/progressive-multifocal-leukoencephalopathy-information-page|work=National Institute of Neurological Disorders and Stroke|publisher=National Institutes of Health|archive-url=https://web.archive.org/web/20200917081254/https://www.ninds.nih.gov/Disorders/All-Disorders/Progressive-Multifocal-Leukoencephalopathy-Information-Page|archive-date=2020-09-17|access-date=2020-09-11|dead-url=no}}</ref>。

==预后==
该病预后不佳，根据患者本身潜在疾病的严重程度，三分之一到二分之一的进行性多灶性白质脑病患者在诊断后的头几个月内死亡。幸存者可能会出现不同程度的神经功能障碍<ref name="NIH" />。

==相关==
* [[多发性硬化|多发性硬化]]

== 参考文献 ==
{{Reflist|30em}}

==外部链接==
* [https://web.archive.org/web/20150104180601/http://www.ninds.nih.gov/disorders/pml/pml.htm Overview] at [[國家衛生院_(美國)|NIH]]
* [https://web.archive.org/web/20060310193401/http://www.clevelandclinic.org/health/health-info/docs/1300/1322.asp?index=6101 Overview] at [[Cleveland_Clinic|Cleveland Clinic]]
* {{eMedicine|neuro|450|HIV-1 Associated Opportunistic Infections: PML}}
* {{MedlinePlusEncyclopedia|000674|Progressive multifocal leukoencephalopathy}}
*[https://web.archive.org/web/20110616124817/http://pml-disease.com/ PML Disease Support Website]

{{-}}
{{中枢神经系统疾病}}

[[Category:大脑病变|Category:大脑病变]]
[[Category:一般性医学状况造成的精神疾病|Category:一般性医学状况造成的精神疾病]]
[[Category:中枢神经系统病毒感染|Category:中枢神经系统病毒感染]]
[[Category:罕见病|Category:罕见病]]